Bicara Therapeutics Inc. Retained Earnings
Bicara Therapeutics Inc. (BCAX) had Retained Earnings of -$470.61 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-11
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$470.61M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$415.18M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$358.97M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$321.58M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$470.61M 10-Q · filed 2026-08-11 |
| 2026-03-31 | -$415.18M 10-Q · filed 2026-05-11 |
| 2025-12-31 | -$358.97M 10-Q · filed 2026-08-11 |
| 2025-09-30 | -$321.58M 10-Q · filed 2025-11-10 |
| 2025-06-30 | -$285.25M 10-Q · filed 2025-08-12 |
| 2025-03-31 | -$257.86M 10-Q · filed 2025-05-13 |
| 2024-12-31 | -$221.02M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$200.06M 10-Q · filed 2024-11-12 |
| 2023-12-31 | -$153.02M 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |